Results 121 to 130 of about 128,993 (222)

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product

open access: yesOphthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar to Eylea® (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases.
Neungseon Seo   +5 more
doaj   +1 more source

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

open access: yesAboutOpen
Background: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been recently reimbursed by AIFA.
Roberto Bergamaschi   +2 more
openaire   +2 more sources

Pharmacovigilance, traceability and building trust in biosimilar medicines

open access: yes, 2017
The Medicines for Europe's Biosimilar Medicines Group met at the 2017 European Association of Hospital Pharmacists conference in France to discuss pharmacovigilance, traceability and building trust in biosimilar ...
Teun van Gelder   +5 more
core   +1 more source

Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

open access: yesRheumatology and Therapy
Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Ran Jin   +8 more
doaj   +1 more source

A practical guide about biosimilar data for health care providers treating inflammatory diseases

open access: yes, 2017
Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc ...
Jacobs I   +3 more
core  

Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference Product

open access: yesOphthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar candidate to aflibercept reference product (RP), a biologic used for certain angiogenic eye disorders.
Neungseon Seo   +14 more
doaj   +1 more source

Financial Analysis of Biosimilar Development Candidates: A Case Study on the US Biosimilar Business

open access: yes, 2016
This case study investigates the US biosimilar business and the approach that should be implemented when financially analyzing biosimilar development candidates.
Gutierrez, Bryan J.
core   +2 more sources

Home - About - Disclaimer - Privacy